Presenting Author details:Micah.Murray@chuv.ch Site de Cery, CH-1008 Prilly-Lausanne, Switzerland, Tel.: +41 21 6436565; fax: +41 21 6436562. Brain imaging methods are improving our general understanding of the brain's functional organization in healthy individuals as well as patients with neuropsychiatric disorders, including schizophrenia. Electrical neuroimaging has proven a particularly reliable means for identifying sensory–cognitive impairments, endophenotypes, and putative rehabilitation strategies in patients with schizophrenia. This technique benefits from real-time temporal information that reveals the spatio-temporal dynamics of brain (dys)function, including details concerning both when different brain areas become active and in what processing step(s) each is involved. Additionally, electrical neuroimaging can reveal effects that may not forcibly manifest either psychophysically or with neuropsychological batteries. First, evidence will be presented showing that sensory–cognitive impairments in visual processing by patients with schizophrenia dissociate between functions associated with the dorsal and ventral visual processing streams. Such findings are providing insights not only regarding the pathophysiology of schizophrenia, but also for models of object processing in healthy individuals. Second, evidence will be presented showing recovery of electrophysiological measures of auditory processing (the mismatch negativity; MMN) following treatment with N-acetyl-cysteine (NAC), a glutathione precursor that in turn is likely to impact NMDA receptor functioning. Following a double-blind and crossover design, NAC treatment significantly improved MMN generation compared with placebo. This improvement was observed in the absence of either measurable effects on the P300 response, which was not deficient relative to healthy controls, or robust changes in assessments of clinical severity. MMN recovery may thus precede changes in standard clinical metrics, highlighting the possible utility of electrical neuroimaging as a biomarker of treatment efficacy.